Evidence map›Paper›PMID 38956542›Full record

SynthesisBMC infectious diseases2024

Epidemiology of Citrobacter spp. infections among hospitalized patients: a systematic review and meta-analysis.

Pérince Fonton, Nasreen Hassoun-Kheir, Stephan Harbarth

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in BMC infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Species identification and genotyping ofMicrobiology spectrum · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. TheInternational journal of molecular sciences · 2026
    Review
  7. Plasmids of the multidrug-resistantMicrobiology spectrum · 2026
    Article
  8. Rising incidence of carbapenem-resistantMicrobiology spectrum · 2026
    Article
  9. Article
  10. Article
  11. Occurrence ofPathogens (Basel, Switzerland) · 2026
    Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Foods (Basel, Switzerland) · 2025
    Article
  17. Article
  18. Article
  19. Genomic characterization of a multidrug-resistantFrontiers in microbiology · 2025
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Pérince FontonInfection Control Program, Geneva University Hospitals and Faculty of Medicine, WHO Collaborating Center, Rue Gabrielle-Perret-Gentil 4, CH-1205, Geneva, Switzerland.
Nasreen Hassoun-KheirInfection Control Program, Geneva University Hospitals and Faculty of Medicine, WHO Collaborating Center, Rue Gabrielle-Perret-Gentil 4, CH-1205, Geneva, Switzerland.
Stephan HarbarthInfection Control Program, Geneva University Hospitals and Faculty of Medicine, WHO Collaborating Center, Rue Gabrielle-Perret-Gentil 4, CH-1205, Geneva, Switzerland. stephan.harbarth@hug.ch.

Funding

Federal Commission for Scholarships for Foreign Students for the Swiss Government Excellence Scholarship ESKAS No. 2022 .0465Innovative Medicines Initiative 2, Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance [PrIMAVeRa] 101034420
6 · The paper itself

Abstract

backgroundInfections due to Citrobacter species are increasingly observed in hospitalized patients and are often multidrug-resistant. Yet, the magnitude and burden of Citrobacter spp. resistance in the hospital setting have not been reported. We aimed to evaluate the epidemiology of Citrobacter spp. infections among hospitalized patients, their main resistance patterns and Citrobacter spp. involvement in hospital outbreaks.

methodsWe conducted a systematic review and meta-analysis of published literature (PROSPERO registration Jan-2023, CRD42023390084). We searched Embase, Medline and grey literature for studies on hospitalized patients diagnosed with Citrobacter spp. infections, and nosocomial outbreaks due to Citrobacter spp. published during the years 2000-2022. We included observational, interventional, surveillance studies and outbreak reports. Outcomes of interest were the frequency of Citrobacter spp. infections among hospitalized patients and 3rd generation cephalosporin and/or carbapenem resistance percentages in these infections. We used random-effects models to generate pooled outcome estimates and evaluated risk of bias and quality of reporting of outbreaks.

resultsWe screened 1609 deduplicated publications, assessed 148 full-texts, and included 41 studies (15 observational, 13 surveillance and 13 outbreak studies). Citrobacter spp. urinary tract- and bloodstream infections were most frequently reported, with Citrobacter freundii being the main causative species. Hospital-acquired infection occurred in 85% (838/990) of hospitalized patients with Citrobacter infection. After 2010, an increasing number of patients with Citrobacter spp. infections was reported in observational studies. Pooled frequency estimates for Citrobacter spp. infections could not be generated due to lack of data. The pooled prevalence of ESBL and carbapenemase producers among Citrobacter isolates were 22% (95%CI 4-50%, 7 studies) and 18% (95%CI 0-63%, 4 studies), respectively. An increased frequency of reported Citrobacter outbreaks was observed after 2016, with an infection/colonization ratio of 1:3 and a case-fatality ratio of 7% (6/89 patients). Common outbreak sources were sinks, toilets, contaminated food and injection material. Implemented preventive measures included environmental cleaning, isolation of positive patients and reinforcement of hand hygiene. Only seven out of 13 outbreaks (54%) were definitively controlled.

conclusionThis review highlights the clinical importance of endemic and epidemic Citrobacter spp. in healthcare settings. As an emerging, multidrug‑resistant nosocomial pathogen it requires heightened awareness and further dedicated surveillance efforts.

Indexed as

CitrobacterCross InfectionEnterobacteriaceae InfectionsAnti-Bacterial AgentsDisease OutbreaksDrug Resistance, Multiple, BacterialHospitalizationHumansUrinary Tract InfectionsAnti-Bacterial AgentsCarbapenem resistant – 3rd generation cephalosporin resistantCitrobacter spp. infectionsHospitalized patientsNosocomial infectionsOutbreak

Identifiers

PMID38956542
PMCPMC11221093

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.